<DOC>
	<DOCNO>NCT00351767</DOCNO>
	<brief_summary>This Phase II , double-blind , randomize , placebo-controlled study evaluate safety efficacy three different dos topically apply telbermin subject ≥ 18 year old diabetic foot ulcer . Approximately 160 adult subject Type 1 Type 2 diabetes mellitus enrol approximately 40 investigational site United States Canada .</brief_summary>
	<brief_title>A Study Assess Effect Topical Recombinant Human Vascular Endothelial Growth Factor Induction Healing Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Ability willingness comply follow : study drug gel application dress change instruct ; use offload footwear practice rub prevention ( shear injury ) study ulcer duration study ; adherence study requirement use adequate caregiver assistance For male female childbearing potential , use effective method contraception Type 1 2 diabetes mellitus Inability perceive 10 gram pressure periulcer area use SemmesWeinstein 5.07 monofilament At least one full thickness ( i.e. , extend subcutaneous tissue beyond ) ulcer foot malleolus involve bone , tendon , ligament , muscle ( University Texas Classification System Diabetic Foot Wounds , Stage 1a ) Estimated foot ulcer surface area , L x W , ≥ 0.70 cm^2 ≤ 5.0 cm^2 measure Treatment Day 1 Any subject meet criterion eligible randomization . Eye examination ( indirect ophthalmoscopy , fundus photography , fluorescein angiography ) within 6 month prior randomization indication proliferative diabetic retinopathy wet agerelated macular degeneration Presence active systemic local cancer tumor kind ( exception nonmelanoma skin cancer ) Proliferative diabetic retinopathy wet agerelated macular degeneration A history pulmonary edema Active congestive heart failure Active infection cellulitis ulcer study foot Active osteomyelitis study foot Active connective tissue disease Study ulcer etiology relate diabetes ( e.g. , thermal , chemical , radiation insult ) History active Charcot foot study foot within 6 month screen Treatment systemic corticosteroid ( equivalent &gt; 10 mg/day prednisone ) immunosuppressive chemotherapeutic agent within 14 day prior first study drug gel application likelihood receive one therapy study participation Previous current radiation therapy distal low extremity likelihood receive therapy study participation Pregnancy lactation Presence two fullthickness ulcer study foot Endstage renal failure necessitate chronic hemodialysis chronic ambulatory peritoneal dialysis Poor nutritional status Life expectancy le 3 year ( opinion investigator ) Known hypersensitivity ingredient telbermin , placebo , vehicle , include excipients formulation telbermin placebo gel Known prior inability complete require study visit study participation A psychiatric condition ( e.g. , suicidal ideation ) chronic alcohol drug abuse problem , determine subject 's medical history , , opinion investigator , may pose threat subject compliance Use plateletderived growth factor within 28 day prior screen Use investigational drug therapy within 28 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Dabetic Feet</keyword>
</DOC>